LAGUNA HILLS, California, Nov. 13, 2020 /PRNewswire/ — Adagio Medical, Inc., a leading innovator for the treatment of atrial
fibrillation (AF) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS), today announced that it has
closed a $42.5 million Series E equity financing. Proceeds from the financing will be used to support
fibrillation (AF) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS), today announced that it has
closed a $42.5 million Series E equity financing. Proceeds from the financing will be used to support
Neueste Kommentare